This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Ellen M. Mandel, MD; Howard E. Rockette, PhD; Charles D. Bluestone, MD; Jack L. Paradise, MD; Robert J. Nozza, PhD
Children's Hospital of Pittsburgh (Pa)

JAMA. 1993;270(4):450.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Dr Cantekin has responded to virtually none of the substance of our article, but instead advances invalid accusations and other misleading statements.

First, as for "special oversight," the OSI noted that "the recommendations concerning operations of the OMRC were not intended as sanctions..." but "were intended to provide safeguards against even the appearance of possible conflict of interest..."^1(p3) The OSI did not find that Dr Bluestone had "financial ties to drug companies." Dr Bluestone had received research support from drug companies and honoraria for presentations at scientific and educational meetings, but the OSI did not find that these funds were "undisclosed." The OSI also did not find "bias."²

Second, the OSI commentary on antibiotic therapy now cited by Cantekin referred not to our New England Journal of Medicine article³ that Cantekin and his coauthors had criticized⁴ and that our JAMA article defended, but rather . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?